Web:AXA/FY25/Activity report/summary
Activity report
- Document type: Activity report
- Entity: AXA
- Period: FY2025
December 31, 2025
- No content was provided in this section.
Table of contents
- Operating highlights — p. 5
- Events subsequent to December 31, 2025 — p. 11
- Market environment — p. 12
- Activity and earnings indicators — p. 18
- Alternative performance measures — p. 23
- Commentary on group earnings — p. 23
- Property & Casualty earnings — p. 24
- Life & Health earnings — p. 26
- Holdings earnings — p. 28
- Net income — p. 28
- Shareholders' equity group share — p. 29
- Solvency information — p. 29
- Shareholder value — p. 30
- Outlook — p. 31
- Glossary — p. 32
Important legal information and cautionary statement regarding forward-looking statements
- Forward-looking statements
- Certain statements in this report may constitute forward-looking statements, identified by terms such as "expects", "anticipates", "may", "plan", conditional verbs ("would", "could"), or similar expressions.
- Statements in the "Outlook" section regarding expected Underlying Earnings per Share (UEPS) growth for the 2023–2026E plan period and for 2026 specifically are forward-looking, provided as one-off guidance in the context of the final year of AXA's current strategic plan.
- Forward-looking statements reflect Management's current views and intentions and are subject to change.
- Undue reliance should not be placed on such statements; they are subject to known and unknown risks and uncertainties, many outside AXA's control, that could cause actual results to differ materially.
- Each forward-looking statement speaks only as of the date of this report.
- Reference is made to Part 5 "Risk Factors and Risk Management" of AXA's Universal Registration Document for the year ended December 31, 2024 (the "2024 Universal Registration Document") for a description of important factors, risks and uncertainties.
- AXA disclaims any obligation to publicly update or revise forward-looking statements, except as required by applicable laws and regulations.1
Use of non-GAAP and alternative performance measures
- This report refers to certain non-GAAP financial measures, also referred to as alternative performance measures (APMs), used by Management to analyze operating trends, financial performance and financial position.
- These measures generally have no standardized meaning and may not be comparable to similarly labelled measures used by other companies.
- None of these measures should be considered in isolation from, or as a substitute for, the Group's Consolidated Financial Statements prepared in accordance with IFRS.
- The following are APMs as defined under ESMA guidelines and the AMF's related 2015 position statement:
- Reconciliations:
- Underlying Earnings and Combined Ratio are reconciled to the most directly comparable IFRS line items on pages 21–22 of this report.
- Underlying Return on Equity and Underlying Earnings per Share are reconciled to the Consolidated Financial Statements in tables on page 30 of this report.
- Further definitions of all APMs are provided in Appendix IV "Glossary", pages 565–566 of the 2024 Universal Registration Document.
- Notes
- 1 The "Risk Factors & Risk Management" section of the 2024 Universal Registration Document will be replaced and superseded in its entirety by the same section in AXA's Universal Registration Document for the year ended December 31, 2025, to be published in March 2026.
Certain terms and other information
- "Company", "AXA" and "AXA SA" refer to AXA, a société anonyme organized under the laws of France, the publicly traded parent company of the AXA Group.
- "AXA Group", "Group" and "we" refer to AXA SA together with its direct and indirect consolidated subsidiaries.
- This report is a translation into English of the 2025 Activity Report originally issued in French, available at www.axa.com.
- AXA's consolidated financial statements for the year ended December 31, 2025, were examined by the Board of Directors on February 25, 2026, and are subject to completion of an audit procedure by AXA's statutory auditors.
- The final version of this report, together with AXA's audited consolidated financial statements, will be included in AXA's 2025 Universal Registration Document to be filed with the AMF in March 2026.
Operating highlights
Governance
- No content available for this section.
AXA's Board of Directors announces its decision to propose the renewal of Thomas Buberl's mandate in 2026
- Announcement date: April 23, 2025.
- Decision maker: AXA's Board of Directors.
- Subject: Proposal to renew Thomas Buberl's mandate as a director.
- Proposed term: Four-year term.
- Approval venue: Annual Shareholders' Meeting to be held in 2026.
- Intended role following renewal: Reappointment as Chief Executive Officer.
- At the Shareholders' Meeting of April 24, 2025, all submitted resolutions were approved, including:
- Renewal of Board mandates of Guillaume Faury and Ramon Fernandez for 4 years.
- Ratification of the co-optation of Ewout Steenbergen as a director.
- Ramon de Oliveira's directorship term ended following the meeting.
Changes within the leadership team
- Changes announced October 17, 2025; effective December 1, 2025.
- Guillaume Borie appointed Global Head of Finance, Strategy, Underwriting, Risk and Technology; continues to report to Thomas Buberl; assumed responsibilities previously held by Frédéric de Courtois.
- Mathieu Godart appointed CEO of AXA France and joined AXA's Management Committee, reporting to Thomas Buberl.
- Karima Silvent appointed Deputy General Secretary, in charge of Human Resources, Audit, Compliance, AXA EssentiALL and GIE AXA, reporting to George Stansfield.
- Matthieu Caillat appointed Group Chief Technology & AI Officer and CEO of AXA Group Operations (role previously held by Alexander Vollert); joined AXA's Management Committee, reporting to Guillaume Borie.
AXA's Management Committee composition as of December 1, 2025:
| Member | Role |
|---|---|
| Thomas Buberl | Group CEO |
| George Stansfield | Group Deputy CEO (Directeur Général Adjoint), General Secretary; oversight of AXA Japan and Greater China (China and Hong Kong) |
| Nancy Bewlay | Group Chief Underwriting Officer |
| Guillaume Borie | Global Head of Finance, Strategy, Underwriting, Risk and Technology |
| Helen Browne | Group General Counsel |
| Matthieu Caillat | Group Chief Technology & AI Officer, CEO of AXA Group Operations |
| Patrick Cohen | CEO of European Markets & Health |
| Ulrike Decoene | Group Chief Communications, Brand and Sustainability Officer |
| Hassan El-Shabrawishi | CEO of International Markets |
| Françoise Gilles | Group Chief Risk Officer |
| Mathieu Godart | CEO of AXA France |
| Scott Gunter | CEO of AXA XL |
| Alban de Mailly Nesle | Group Chief Financial Officer |
| Karima Silvent | Deputy General Secretary, in charge of Human Resources, Compliance, Audit, AXA EssentiALL and GIE AXA |
| Anu Venkataraman | Group Chief Strategy Officer and Head of Investor Relations |
Appointment of Ewout Steenbergen as Chair of its Audit Committee
- On December 11, 2025, the Board of Directors appointed Ewout Steenbergen as Chair of the Audit Committee.
- He succeeds Isabel Hudson, who stepped down from the AXA Board of Directors on December 31, 2025.
Significant transactions
AXA completed the acquisition of Nobis Group
- Completed April 1, 2025.
- Upfront consideration: Euro 423 million; potential earn-out of up to Euro 55 million (conditional on revenue targets over five years post-closing).
- Solvency II ratio impact: -1 point in Q2 2025, in line with expected impact announced at signing (August 1, 2024).
AXA completed the sale of AXA Investment Managers to BNP Paribas
- Completed July 1, 2025.
- Cash proceeds: Euro 5.1 billion for 100% of AXA IM share capital (98% owned by AXA Group).
- Sale of Select to AXA IM closed for Euro 0.3 billion, bringing total transaction value to Euro 5.4 billion.
- Select (formerly Architas) completed in two tranches: Euro 0.1 billion (March 2024) and Euro 0.2 billion (March 2025).
- Post-transaction partnership: BNP Paribas provides investment management services to AXA; AXA retains full authority over product design, asset allocation and asset-liability management.
- Combined AXA IM and BNP Paribas entity creates a leading European asset manager with Euro 1.5 trillion in assets under management (as of December 31, 2024).
Financial impacts:
- One-off net income gain of ca. Euro 2.2 billion.
- Expected reduction in Underlying Earnings of ca. Euro 0.4 billion on an annualized basis.
- Solvency II ratio impact: ca. +2 points in Q3 2025 (including associated share buy-back program).
- No material impact expected on key financial targets under the 'Unlock the Future' plan (Underlying EPS CAGR 2023–2026E of 6%–8%; Underlying return on equity of 14%–16% over 2024–2026E; cumulative organic cash upstream of over Euro 21 billion over 2024–2026E).
AXA completed the acquisition of a majority stake in Prima
- Completed November 28, 2025.
- Prima operates as a Managing General Agent (MGA); launched in 2015; leading direct insurance player in Italy.
- Prima key metrics (2024): Euro 1.2 billion in premiums; ca. 10% overall market share in Retail Motor (estimate based on policy count); combined ratio of 90% (estimated all-year discounted, combining Prima and third-party carriers' margins).
- AXA acquired 51% of Prima for Euro 0.5 billion; a further stake of up to 2% expected to be acquired after closing on the same terms.
- Call/ put options entered into with minority stakeholders for AXA to acquire the remaining stake; expected to be exercised in 2029 or 2030 at a price tied to Prima's earnings.
- Strategic rationale: almost doubles AXA's Motor business in Italy; bolsters direct distribution channel (which generated Euro 3.5 billion in premiums for the Group in 2024).
- Solvency II ratio impact: -3 points upon closing (cost of 51% acquisition plus net present value of remaining stake acquisition via put/call options, per Solvency II requirements); additional -2 points expected over time tied to planned progressive re-capture of premiums currently underwritten by third-party insurance carriers.
- AXA expects to recapture 100% of premiums currently written in Italy and Spain by third-party insurers; recapture expected to start by end of 2026 (subject to regulatory approval).
- Transaction announced at signing on August 1, 2025.
- Agreement execution: On February 28, 2025, AXA executed a share repurchase agreement with an investment services provider to buy back its own shares for a maximum amount of Euro 1.2 billion, consistent with its capital management policy and as announced on February 27, 2025.
- Execution period: Purchases commenced on March 3, 2025 and the program was completed on May 19, 2025.
- Total amount repurchased: Euro 1,199,999,980 (exact amount), carried out under the applicable Shareholders' Meeting authorization (granted April 23, 2024 and, as applicable, April 24, 2025).
- Pricing mechanism: The price per share paid by AXA on each day during the purchase period was determined based on the volume-weighted average share price, not exceeding the maximum purchase price approved at the applicable Shareholders' Meeting.
- Share cancellation: AXA has cancelled all shares repurchased pursuant to this program.
- Context: This Euro 1.2 billion program was executed in addition to any other share buybacks consistent with AXA's capital management policy, including the previously announced Euro 3.8 billion buy-back to be launched following the closing of the sale of AXA Investment Managers to BNP Paribas.
Debt issuances — May 2025
- On May 28, 2025, AXA announced the placement of two tranches of notes with institutional investors, totalling Euro 2 billion.
- Both issuances form part of AXA Group's funding plan for 2025; proceeds are for general corporate purposes, including refinancing of part of AXA Group's outstanding debt.
- Settlement of both tranches took place on June 2, 2025.
Restricted Tier 1 notes (Euro 1 billion)
- Instrument type: Reg S perpetual deeply subordinated notes.
- Interest rate: Fixed at 5.750% per annum until December 2, 2030 (last day of the 6-month call window); thereafter resets every five years at the prevailing Euro 5-year Mid Swap rate plus a margin of 359.9 basis points.
- Regulatory classification: Qualifies as Restricted Tier 1 capital under Solvency II; treated as capital from a regulatory and rating agency perspective within applicable limits.
- Loss absorption: Features a write-down mechanism (with discretionary reinstatement subject to conditions) of the nominal amount if a solvency-related trigger is breached, either at AXA Group level or at AXA SA solo level, as defined in the Prospectus dated May 28, 2025.
- Interest discretion: Interest payments are at the full discretion of AXA unless mandatorily prohibited.
- Credit ratings: BBB+ (Standard & Poor's) / Baa1(hyb) (Moody's).
Tier 2 notes (Euro 1 billion)
- Instrument type: Reg S subordinated notes due 2055.
- Interest rate: Fixed at 4.375% per annum until July 24, 2035 (last day of the 6-month call window); thereafter a floating rate based on 3-month EURIBOR plus a margin of 290 basis points.
- Regulatory classification: Qualifies as Tier 2 capital under Solvency II; treated as capital from a regulatory and rating agency perspective within applicable limits.
- Credit ratings: A- (Standard & Poor's) / A2(hyb) (Moody's).
Key facts
Share repurchase program — Shareplan 2025 and stock-based compensation
- On June 2, 2025, AXA executed a share repurchase agreement with an investment services provider for a maximum amount of Euro 724.6 million.
- Purposes of the buy-back:
- Eliminate the expected dilutive impact of AXA Group's employee share offering (Shareplan 2025).
- Cover the expected future delivery of shares under certain stock-based compensation schemes ( performance shares plans).
- Program size was based on the expected number of shares to be issued under Shareplan 2025 and delivered under relevant stock-based compensation schemes.
- Executed under the Shareholders' Meeting authorization granted on April 24, 2025.
- Buy-back period: June 3, 2025 to June 30, 2025.
- Daily purchase price determined on the basis of the volume-weighted average share price; did not exceed the maximum purchase price approved at the applicable Shareholders' Meeting.
- Shares repurchased have either been cancelled or are to be delivered to beneficiaries of the relevant stock-based compensation schemes.
- This program was executed in addition to any other share buy-backs consistent with AXA's capital management policy, including the Euro 3.8 billion buy-back launched following the closing of the sale of AXA IM to BNP Paribas.
- On July 1, 2025, AXA executed a share repurchase agreement with an investment services provider for a maximum amount of Euro 3.8 billion.
- Purpose: offset the earnings dilution from the sale of AXA Investment Managers to BNP Paribas, as announced on August 1, 2024.
- Executed under the terms of the applicable Shareholders' Meeting authorization.
- Buy-back period: July 2, 2025 to January 19, 2026; exact amount repurchased: Euro 3,799,999,987.
- Daily purchase price determined on the basis of the volume-weighted average share price; did not exceed the maximum purchase price approved at the applicable Shareholders' Meeting.
- AXA is progressively cancelling all shares repurchased under this program.
Employee share offering
- On September 10, 2025, AXA Group announced an employee share offering (Shareplan 2025) open to employees in France and internationally.
- Capital increase took place in December 2025.
- Participation: approximately 42,000 employees across 40 countries, representing more than 36% of eligible employees.
- Total capital increase: approximately Euro 411 million (excluding matching contribution; see note below).
- Total new shares issued: approximately 13 million.
- Subscription prices: Euro 31.66 (Classic offer) and Euro 37.04 (Guarantee Plus offer).
- Total outstanding AXA shares following Shareplan 2025: 2,136,232,264 as of December 3, 2025.
- Post-Shareplan employee ownership: 4.82% of AXA share capital and 6.61% of voting rights.
- To eliminate dilutive effect, AXA bought back its own shares for cancellation under the June 2, 2025 share repurchase program.
- Additional matching contribution: 751,317 shares issued and given for free to employees to celebrate the 40th anniversary of the AXA brand; IFRS charge of Euro 24 million (capital increase and reduction of share premium by Euro 1.7 million in statutory accounts).
Debt issuance — October 2025
- On October 14, 2025, AXA announced the placement of two tranches of notes with institutional investors, totalling Euro 1.5 billion, as part of AXA Group's funding plan.
- Proceeds used for general corporate purposes, including refinancing of part of AXA Group's outstanding debt.
- Settlement date: October 16, 2025.
| Metric | Unit | Restricted Tier 1 Notes | Tier 2 Notes |
|---|---|---|---|
| Issuance amount | Euro million | 750 | 750 |
| Format | — | Reg S perpetual deeply subordinated notes | Reg S subordinated notes due 2056 |
| Fixed interest rate | % p.a. | 5.125% until March 16, 2032 | 4.125% until July 24, 2036 |
| Rate after call window | — | Reset every 5 years at Euro 5-year Mid Swap rate + 278.4 bps | Floating: 3-month EURIBOR + 258 bps |
| Call window end date | — | March 16, 2032 (last day of 6-month window) | July 24, 2036 (last day of 6-month window) |
| Regulatory classification | — | Restricted Tier 1 capital (Solvency II) | Tier 2 capital (Solvency II) |
| Loss absorption mechanism | — | Write-down of nominal amount if solvency trigger breached (at AXA Group or AXA SA solo level); discretionary reinstatement subject to conditions | None specified |
| Interest payment discretion | — | Full discretion of AXA unless mandatorily prohibited | Not specified |
| S&P rating | — | BBB+ | A- |
| Moody's rating | — | A3 (hyb) | A1 (hyb) |
| Treatment | — | Capital (regulatory and rating agency perspective, within applicable limits) | Capital (regulatory and rating agency perspective, within applicable limits) |
Events subsequent to December 31, 2025
- Approval and authorization
- AXA's Board of Directors approved the launch of an annual share buy-back program on February 25, 2026.
- Maximum program size: Euro 1.25 billion.
- To be executed in accordance with the applicable Shareholders' Annual General Meeting (AGM) authorization.1
- AXA intends to cancel all shares repurchased under the program.
- Timing and execution
- Program expected to commence as soon as reasonably practicable, subject to market conditions.
- Expected to be completed by year-end 2026.
- Further details on execution to be communicated in due course.
- Notes
- 1 To be executed in accordance with the terms of the AGM authorization granted on April 24, 2025, or the authorization expected to be granted by the AGM on April 30, 2026, as applicable.
Market environment
- Macroeconomic context
- No macroeconomic context data was provided in this section.
- Note
- The section content was empty; no market environment information was included in the source document for this reporting period.
Financial market conditions
Stock markets
📈 Main equity index levels and YoY change, FY2024–FY2025
| Index | Dec 31, 2025 (pts) | YoY FY25 | Dec 31, 2024 (pts) | YoY FY24 | Comments |
|---|---|---|---|---|---|
| CAC 40 | 8,150 | +10% | 7,381 | -2% |
|
| Eurostoxx 50 | 5,791 | +18% | 4,896 | +8% |
|
| FTSE 100 | 9,931 | +22% | 8,173 | +6% |
|
| Nikkei | 50,339 | +26% | 39,895 | +19% |
|
| S&P 500 | 6,846 | +16% | 5,882 | +23% |
|
| MSCI World | 4,430 | +19% | 3,708 | +17% |
|
| MSCI Emerging | 1,404 | +31% | 1,075 | +5% |
|
Source: Bloomberg.
Residual context:
- Overall backdrop: despite ongoing geopolitical and macroeconomic uncertainties, global equity markets delivered another year of solid performance in 2025.
- Key macro tailwinds: disinflation trends, clearer monetary policy signals, and resilient corporate earnings supported equities across regions.
Bond markets
📈 10-year government bond yields and changes, FY2023–FY2025
| Government bond | Unit | Dec 31, 2025 | YoY (2025 vs 2024) | Dec 31, 2024 | YoY (2024 vs 2023) | Comments |
|---|---|---|---|---|---|---|
| 10Y French bond | % / bps | 3.56% | +37 bps | 3.20% | +64 bps |
|
| 10Y German bond | % / bps | 2.86% | +49 bps | 2.37% | +34 bps |
|
| 10Y Swiss bond | % / bps | 0.32% | -1 bps | 0.33% | -38 bps |
|
| 10Y Italian bond | % / bps | 3.55% | +3 bps | 3.52% | -18 bps |
|
| 10Y UK bond | % / bps | 4.48% | -9 bps | 4.57% | +103 bps |
|
| 10Y Japanese bond | % / bps | 2.07% | +97 bps | 1.10% | +49 bps |
|
| 10Y US bond | % / bps | 4.17% | -40 bps | 4.57% | +69 bps |
|
Source: Bloomberg.
Residual context:
- Global bond markets showed divergent yield trends in 2025, reflecting differences in monetary policy paths, fiscal dynamics, and growth expectations across regions.
- ECB: reduced policy rates four times, bringing the deposit rate to 2% by year-end.
- Corporate spreads: tightened further through 2025; U.S. credit spreads narrowed to their tightest levels since 1998, reflecting strong fundamentals and optimism; European spreads also compressed sharply across both investment grade and high yield.
Exchange rates
📈 End of period and average exchange rates vs EUR, FY2025 and YoY change
| Currency (for €1) | Unit | End of period rate Dec 31, 2025 | End of period YoY | Average rate FY2025 | Average rate YoY | Comments |
|---|---|---|---|---|---|---|
| US Dollar | USD | 1.17 | +13% | 1.13 | +5% |
|
| British Pound Sterling | GBP | 0.87 | +6% | 0.86 | +1% |
|
| Swiss Franc | CHF | 0.93 | -1% | 0.94 | -2% |
|
| Japanese Yen | JPY | 184 | +13% | 169 | +3% |
|
Source: WM/Refinitiv.
Insurance market conditions
Main developed markets
France — savings and life insurance
- Savings insurance market up 10% YoY; total premiums reached €192 billion.
- Unit-linked products: ↑ +13%; General Account: ↑ +8%.
- Unit-linked share rose slightly to 39% (vs. 38% in 2024).
- Rising saving ratio supported net flows; 'Livret A' rate cut to 1.7% ↑ demand.
- Surrenders ↓ in both General Account and Unit-linked funds.
- Total outstanding Life insurance assets: €2,107 billion (+6%), a new record.
- 'PER' retirement plan premiums: €20 billion (+16%).
France — protection, health and natural catastrophes
- Medical inflation, ↑ absenteeism and regulatory changes (incl. IJSS reform) drove cost pressure in Protection and complementary Health.
- Average tariff increase of ~6% partly absorbed these pressures.
- Natural disasters in 2025: storm Garance (~€0.2bn), storm Benjamin (~€0.3bn), plus droughts, floods and hailstorms.
- Total estimated cost to insurers from climate-related events: >€10 billion in 2025 (vs. €5 billion in 2024), reinforcing a long-term upward trend.
Europe — P&C, Life and Health
- P&C: benign natural catastrophe losses; profitability remained favorable following multi-year pricing measures; economic and geopolitical uncertainty persisted.
- Life: moderate growth despite ↑ US trade tariff pressure; favorable equity markets and persistently high long-term interest rates ↑ demand.
- Strong demand for Unit-Linked savings; traditional guaranteed savings maintained momentum.
- Health: aging population, ↑ claims costs and pressure on national healthcare systems prompted price increases; insurers differentiating via services, vertical integration and digital transformation.
Japan
- Life GWP ↓ 2.4%, mainly due to ↓ sales of foreign-currency single-premium products; Unit-Linked segment continued to grow, attracting new entrants.
- P&C GWP ↑ 4%, driven by price increases in Motor and Fire insurance.
Hong Kong
- Life GWP ↑ 37%; new business ↑ 56% (General Account +55%, Unit-Linked +76%).
- P&C GWP ↑ 9.3%.
United States
- Commercial insurance transitioning toward a more competitive environment.
- Moderating pricing in short-tail lines; persistent casualty pressure from social inflation.
- Overall profitability remained robust, reflecting strong prior-year price increases.
Global outlook and reinsurance
- Insurers well positioned to address underinsured/uninsured segments and emerging risks.
- Investment in AI and data modernization to ↑ efficiency and underwriting accuracy.
- Climate change, casualty trends, AI adoption and demographic shifts generating new insurable assets and market opportunities.
- Reinsurance sector: additional market softening projected for 2026; profitability expected to remain strong, with return on equity continuing to exceed cost of capital.
Main emerging markets
Asia emerging markets
- P&C: growth across most geographies — Motor ↑ in China and Philippines; Property ↑ in Thailand and Philippines.
- Life:
- Thailand: new business ↑ 5%, driven by migration toward Endowment products amid low interest rates.
- Philippines: volumes ↑ 15%, supported by Endowment products and Corporate Solutions.
- Indonesia: low persistency in Unit-Linked products, partially offset by new Endowment and Protection product launches.
Other emerging markets
- Mexico: market ↑ 12%; Non-Motor lines ↑ 17% (federal catastrophe risk transfer to private sector); Life ↑ 10% ( Bancassurance); Health ↑ 11% (Group business). Legislative change in October 2025 removed VAT recoverability on third-party claims (hospitals, Motor repairs), creating material profitability pressure and expected to drive price increases and product adjustments.
- Colombia: market ↑ 8%, driven by Workers' Compensation, Group Life and Health; partly offset by softening in Motor and Liability.
- Türkiye: P&C market ↑ 43%, mainly driven by ~30% inflation; underlying volume growth in Motor and Health from ↑ customer demand for protection solutions.
📈 AXA — Property & Casualty and Life insurance market ranking and market share by country, various periods
| Country | P&C ranking | P&C market share (%) | Life ranking | Life market share (%) | Sources |
|---|---|---|---|---|---|
| France | 2 | 13.2 | 6 | 7.4 | France Assureurs as of December 31, 2025. |
| Switzerland | 1 | 13.3 | 3 | 10.0 | SIA (Swiss Insurance Association) figures as of February 5, 2026; market share based on statutory premiums and market estimations. |
| Germany | 4 | 5.2 | 7 | 3.4 | GDV (German association of Insurance companies) as of December 31, 2024. |
| Belgium | 2 | 16.7 | 5 | 6.8 | Assuralia based on GWP as of December 31, 2024, extrapolated to December 31, 2025 using actual Q3 growth. |
| United Kingdom | 6 | 6.0 | — | — | Association of British Insurers (retail) and GlobalData report (Commercial). |
| Ireland | 1 | 17.2 | — | — | Insuranceireland.eu FactFile 2024. |
| Spain | 6 | 5.7 | 8 | 3.0 | ICEA (Spanish Association of Insurance Companies) as of December 31, 2025. |
| Italy | 4 | 7.2 | 10 | 3.1 | ANIA (Associazione Nazionale Imprese Assicuratrici) as of December 31, 2024. |
| Japan | 14 | 0.5 | 10 | 4.1 | Disclosed financial reports (excl. KampoLife) for the 12 months ended September 30, 2025. |
| Hong Kong | 2 | 9.2 | 9 | 5.0 | Insurance Authority statistics; Life GWP as of September 30, 2025 and P&C GWP as of December 31, 2024. |
| XL Insurance in the United States | 16 | 1.5 | — | — | AMBest 2024 as of December 31, 2024 — Bestlink US Commercial Group Ranking. |
| Thailand | 13 | 2.2 | 5 | 7.2 | TGIA as of October 31, 2025 and TLAA as of October 31, 2025. |
| Indonesia | — | — | 5 | 7 | AAJI report for Weighted New Business Premiums as of September 30, 2025. |
| Philippines | 8 | 3.0 | 6 | 20 (TPI) / 27.3 (NBAPE) | Life Insurance Commission; life total premium income and P&C GWP both as of September 30, 2025. |
| China | — | 0.3 | — | — | NFRA (National Financial Regulatory Administration) as of December 31, 2025. (a) |
| Mexico | 4 | 7.9 | 11 | 1.6 | AMIS (Asociación Mexicana de Instituciones de Seguros) as of September 30, 2025. |
| Brazil | 11 | 2.7 | — | — | SUSEP (Superintendência de Seguros Privados) as of October 31, 2025. |
| Colombia | 3 | 9.4 | 12 | 1.0 | Fasecolda as of November 30, 2025. |
| Türkiye | 4 | 83 | — | — | Insurers association as of November 30, 2025. |
(a) For the P&C insurance market, NFRA did not disclose information on ranking. For the Life insurance market, NFRA did not disclose information on market shares and ranking.
Activity and earnings indicators
Activity indicators
📈 GWP & other revenues, NBV, PVEP, NBV margin, NBCSM, net flows by line of business (EUR mm), FY24–FY25
| Metric | Unit | FY25 | FY24 | FY25 / FY24 (a) | Comments |
|---|---|---|---|---|---|
| GWP & other revenues (b) | EUR mm | 115,524 | 110,316 | +6.5% | ↑ +4.7% reported; comparable basis restatements of €+2.0bn (+1.8 pts) from scope (Nobis acquisition, Laya underwriting on AXA Ireland balance sheet, AXA IM disposal) and FX (EUR appreciation vs. USD, TRY, MXN, HKD; partly offset by depreciation vs. CHF) |
| Property & Casualty | EUR mm | 58,038 | 56,514 | +5.2% |
|
| o/w Life | EUR mm | 37,499 | 34,497 | +9.5% |
|
| o/w Health | EUR mm | 19,014 | 17,486 | +5.2% |
|
| Asset Management (c) | EUR mm | 875 | 1,701 | n.m. |
|
| Banking | EUR mm | 99 | 118 | -16.2% |
|
| New business value (NBV) (1) | EUR mm | 2,233 | 2,264 | -0.2% |
|
| Present value of expected premiums (PVEP) (2) | EUR mm | 49,357 | 50,896 | -2.4% |
|
| NBV margin (1)/(2) | pts | 4.5% | 4.4% | +0.1 pt |
|
| NBCSM | EUR mm | 2,199 | 2,169 | +2.7% |
|
| Net flows | EUR bn | 5,397 | 1,483 | n.m. |
|
(a) Changes are on comparable basis. (b) Net of intercompany eliminations. (c) AXA IM FY25 contribution corresponds to its effective consolidation period, i.e. until July 1, 2025.
📈 GWP & other revenues by geographic segment (EUR mm), FY24–FY25
| Segment | Unit | FY25 | FY24 | FY25 / FY24 (a) | Comments |
|---|---|---|---|---|---|
| GWP & other revenues (b) | EUR mm | 115,524 | 110,316 | +6.5% | ↑ Broad-based growth across all geographic segments |
| France | EUR mm | 30,598 | 28,996 | +5.9% |
|
| Europe | EUR mm | 43,005 | 39,298 | +5.6% |
|
| AXA XL | EUR mm | 19,277 | 19,383 | +3.8% |
|
| Asia, Africa & EME-LATAM | EUR mm | 19,925 | 19,083 | +12.8% |
|
| AXA IM (c) | EUR mm | 875 | 1,701 | n.m. |
|
| Transversal & other | EUR mm | 1,844 | 1,856 | -1.3% |
|
(a) Changes are on comparable basis. (b) Net of intercompany eliminations. (c) AXA IM FY25 contribution corresponds to its effective consolidation period, i.e. until July 1, 2025.
```wikitable
| Metric | Unit | Dec 31, 2024 | France | Europe | AXA XL | Asia, Africa & EME-LATAM | AXA IM | Transversal & Other | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Short-term business | |||||||||
| Revenues | EUR mm | 72,104 | 18,698 | 24,005 | 18,530 | 8,750 | n.a. | 2,122 |
|
| Technical margin | EUR mm | 5,421 | 1,470 | 1,957 | 1,820 | 81 | — | 93 |
|
| Long-term business | |||||||||
| CSM release | EUR mm | 2,775 | 823 | 920 | 3 | 1,029 | — | 0 |
|
| Technical experience | EUR mm | (95) | (96) | (8) | 2 | 7 | — | 0 |
|
| Financial results & other | |||||||||
| Financial results | EUR mm | 3,971 | 613 | 1,486 | 616 | 741 | 35 | 480 |
|
| Other revenues | EUR mm | 3,054 | 108 | (32) | 0 | 0 | 2,004 | 974 |
|
| Other expenses | EUR mm | (3,479) | (180) | (25) | 0 | (20) | (1,493) | (1,761) |
|
| Debt financing charges | EUR mm | (948) | 0 | (2) | (33) | (12) | 0 | (902) |
|
| Underlying earnings before tax | EUR mm | — | — | — | — | — | — | — | Note: full row values not provided in source extract |
Residual information not captured in the table
- Scope of the section: The section covers the derivation of underlying earnings from segment-level operating lines through to net income group share, spanning both short-term (P&C) and long-term (Life & Health) business activities.
- Short-term business — combined ratio: A combined ratio line is present in the source structure but no values were disclosed in this extract; it is a key performance indicator for the P&C segments (France, Europe, AXA XL).
- Long-term business — CSM mechanics: The CSM (Contractual Service Margin) release line reflects the systematic unwinding of deferred profit under IFRS 17; Asia, Africa & EME-LATAM's high contribution (1,029 out of 2,775 total) signals a large and growing long-term in-force portfolio in that region.
- AXA IM positioning: AXA IM revenues and expenses are almost entirely captured under "Other revenues" and "Other expenses," consistent with its asset-management fee-based model rather than underwriting income.
- Debt financing charges concentration: Virtually all group debt charges (902 out of 948) sit in Transversal & Other, reflecting AXA's centralised treasury and holding-company funding structure.
- Below-the-line items (not shown in extract): The full section would typically continue with income tax, minority interests,and adjustments (e.g., net realised gains/losses, restructuring charges, goodwill impacts) to reconcile underlying earnings before tax to net income group share.